JGC
ZBIO icon

J. Goldman & Co’s Zenas BioPharma ZBIO Stock Holding History

J. Goldman & Co’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73M Buy
68,232
+31,435
+85% +$625K 0.04% 366
2026
Q1 		$719K Buy
+36,797
New +$826K 0.02% 461

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

J. Goldman & Co's ZBIO Position: Q2 2026 in Review

J. Goldman & Co increased its Zenas BioPharma (ZBIO) stake by 85% in Q2 2026, buying an estimated $625K and bringing the position to 68,232 shares worth $1.73M. The position accounts for 0.04% of the portfolio, ranked #366.

J. Goldman & Co first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • J. Goldman & Co held 68,232 shares of Zenas BioPharma worth $1.73M as of Q2 2026.
  • J. Goldman & Co bought 31,435 Zenas BioPharma shares in Q2 2026, an estimated $625K.
  • Zenas BioPharma made up 0.04% of J. Goldman & Co's portfolio in Q2 2026, its #366 holding.
  • J. Goldman & Co first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.